Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.
Destache
Christopher J
CJ
Department of Pharmacy Practice, Creighton University School of Pharmacy & Health Professions, Omaha, NE, USA. destache@creighton.edu
D015526:AIDS Dementia Complex / Q000188:drug therapy*; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000821:virology; D003102:Colloids / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000187:drug effects / Q000378:metabolism; D053758:Nanoparticles / Q000627:therapeutic use*; D009480:Neuropharmacology / Q000379:methods* / Q000639:trends
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D044966:Anti-Retroviral Agents; D003102:Colloids; D027425:ATP-Binding Cassette, Sub-Family C Proteins